Inspire Pharmaceuticals has reached a settlement agreement with the Securities and Exchange Commission, ending a formal investigation into the company's clinical studies for an experimental dry-eye medication, according to a regulatory filing. The SEC probe stemmed from allegations that Inspire omitted information and made false statements in its reports to investors.

Related Summaries